BCEAB | chymase inhibitor

MedKoo Cat#: 128142 | Name: BCEAB

Description:

WARNING: This product is for research use only, not for human or veterinary use.

BCEAB is a chymase inhibitor.

Chemical Structure

BCEAB

CAS#N/A

Theoretical Analysis

MedKoo Cat#: 128142

Name: BCEAB

CAS#: N/A

Chemical Formula: C35H34N2O6

Exact Mass: 578.2417

Molecular Weight: 578.67

Elemental Analysis: C, 72.65; H, 5.92; N, 4.84; O, 16.59

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

BCEAB

IUPAC/Chemical Name

4-(((2S,3S)-1-((di-p-tolylmethyl)carbamoyl)-3-(2-ethoxybenzyl)-4-oxoazetidin-2-yl)oxy)benzoic acid

InChi Key

IGIOAZWNIRIBNB-CPBHLAHYSA-N

InChi Code

InChI=1S/C35H34N2O6/c1-4-42-30-8-6-5-7-27(30)21-29-32(38)37(33(29)43-28-19-17-26(18-20-28)34(39)40)35(41)36-31(24-13-9-22(2)10-14-24)25-15-11-23(3)12-16-25/h5-20,29,31,33H,4,21H2,1-3H3,(H,36,41)(H,39,40)/t29-,33+/m1/s1

SMILES Code

CCOC1=CC=CC=C1C[C@H]2[C@@H](N(C2=O)C(=O)NC(C3=CC=C(C=C3)C)C4=CC=C(C=C4)C)OC5=CC=C(C=C5)C(=O)O

Appearance

To be determined

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 578.67 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Faure A, Manuse S, Gonin M, Grangeasse C, Jault J-M, Orelle C. Daptomycin avoids drug resistance mediated by the BceAB transporter in Streptococcus pneumoniae. Microbiol Spectr. 2024 Feb 6;12(2):e0363823. doi: 10.1128/spectrum.03638-23. Epub 2024 Jan 12. PMID: 38214521; PMCID: PMC10846014. 2: Kobras CM, Piepenbreier H, Emenegger J, Sim A, Fritz G, Gebhard S. BceAB-Type Antibiotic Resistance Transporters Appear To Act by Target Protection of Cell Wall Synthesis. Antimicrob Agents Chemother. 2020 Feb 21;64(3):e02241-19. doi: 10.1128/AAC.02241-19. PMID: 31871088; PMCID: PMC7038271. 3: Bernard R, Guiseppi A, Chippaux M, Foglino M, Denizot F. Resistance to bacitracin in Bacillus subtilis: unexpected requirement of the BceAB ABC transporter in the control of expression of its own structural genes. J Bacteriol. 2007 Dec;189(23):8636-42. doi: 10.1128/JB.01132-07. Epub 2007 Sep 28. PMID: 17905982; PMCID: PMC2168949. 4: George NL, Schilmiller AL, Orlando BJ. Conformational snapshots of the bacitracin sensing and resistance transporter BceAB. Proc Natl Acad Sci U S A. 2022 Apr 5;119(14):e2123268119. doi: 10.1073/pnas.2123268119. Epub 2022 Mar 29. PMID: 35349335; PMCID: PMC9169098. 5: Gottstein J, Zaschke-Kriesche J, Unsleber S, Voitsekhovskaia I, Kulik A, Behrmann LV, Overbeck N, Stühler K, Stegmann E, Smits SHJ. New insights into the resistance mechanism for the BceAB-type transporter SaNsrFP. Sci Rep. 2022 Mar 10;12(1):4232. doi: 10.1038/s41598-022-08095-2. PMID: 35273305; PMCID: PMC8913810. 6: Ohki R, Giyanto, Tateno K, Masuyama W, Moriya S, Kobayashi K, Ogasawara N. The BceRS two-component regulatory system induces expression of the bacitracin transporter, BceAB, in Bacillus subtilis. Mol Microbiol. 2003 Aug;49(4):1135-44. doi: 10.1046/j.1365-2958.2003.03653.x. PMID: 12890034. 7: Furtmann F, Porta N, Hoang DT, Reiners J, Schumacher J, Gottstein J, Gohlke H, Smits SHJ. Characterization of the nucleotide-binding domain NsrF from the BceAB-type ABC-transporter NsrFP from the human pathogen Streptococcus agalactiae. Sci Rep. 2020 Sep 16;10(1):15208. doi: 10.1038/s41598-020-72237-7. PMID: 32938989; PMCID: PMC7494861. 8: Takai S, Jin D, Sakaguchi M, Kirimura K, Miyazaki M. An orally active chymase inhibitor, BCEAB, suppresses heart chymase activity in the hamster. Jpn J Pharmacol. 2001 May;86(1):124-6. doi: 10.1254/jjp.86.124. PMID: 11430464. 9: Takai S, Jin D, Sakaguchi M, Katayama S, Muramatsu M, Sakaguchi M, Matsumura E, Kim S, Miyazaki M. A novel chymase inhibitor, 4-[1-([bis-(4-methyl- phenyl)-methyl]-carbamoyl)3-(2-ethoxy-benzyl)-4-oxo-azetidine-2-yloxy]-benzoic acid (BCEAB), suppressed cardiac fibrosis in cardiomyopathic hamsters. J Pharmacol Exp Ther. 2003 Apr;305(1):17-23. doi: 10.1124/jpet.102.045179. PMID: 12649348. 10: Kingston AW, Zhao H, Cook GM, Helmann JD. Accumulation of heptaprenyl diphosphate sensitizes Bacillus subtilis to bacitracin: implications for the mechanism of resistance mediated by the BceAB transporter. Mol Microbiol. 2014 Jul;93(1):37-49. doi: 10.1111/mmi.12637. Epub 2014 May 23. PMID: 24806199; PMCID: PMC4077933. 11: Reiners J, Lagedroste M, Ehlen K, Leusch S, Zaschke-Kriesche J, Smits SHJ. The N-terminal Region of Nisin Is Important for the BceAB-Type ABC Transporter NsrFP from Streptococcus agalactiae COH1. Front Microbiol. 2017 Aug 29;8:1643. doi: 10.3389/fmicb.2017.01643. PMID: 28912758; PMCID: PMC5583591. 12: Muramatsu M, Yamada M, Takai S, Miyazaki M. Suppression of basic fibroblast growth factor-induced angiogenesis by a specific chymase inhibitor, BCEAB, through the chymase-angiotensin-dependent pathway in hamster sponge granulomas. Br J Pharmacol. 2002 Oct;137(4):554-60. doi: 10.1038/sj.bjp.0704893. PMID: 12359638; PMCID: PMC1573517. 13: Kallenberg F, Dintner S, Schmitz R, Gebhard S. Identification of regions important for resistance and signalling within the antimicrobial peptide transporter BceAB of Bacillus subtilis. J Bacteriol. 2013 Jul;195(14):3287-97. doi: 10.1128/JB.00419-13. Epub 2013 May 17. PMID: 23687272; PMCID: PMC3697649. 14: Okamoto Y, Takai S, Miyazaki M. Chymase inhibitor, BCEAB, suppressed peritoneal adhesion formation in hamster. J Surg Res. 2002 Oct;107(2):219-22. doi: 10.1006/jsre.2002.6515. PMID: 12429178.